Lactobacillus Plantarum and Uses Thereof

• US 20120020943A1
• Filed: 08/25/2010
• Published: 01/26/2012
• Est. Priority Date: 07/20/2010
• Status: Active Grant

• Current Assignee: China Medical University
• Original Assignee: China Medical University
• Inventors: Lin, Wen-Hsin
• Granted Patent: US 8,415,135 B2
• Time in Patent Office: Days
• US Class Current: 424/93.45
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A61K 2035/115 Probiotics
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C12N 1/20 Bacteria; Culture media therefor
• CPC Class Codes: C12N 1/205 Bacterial isolates
• CPC Class Codes: C12R 2001/25 Lactobacillus plantarum

Abstract

Provided is an isolated Lactobacillus plantarum CMU995, which was deposited at the Food Industry Research and Development Institute in Taiwan with the accession number BCRC 910472 and in the German Collection of Microorganisms and Cell Cultures (DSMZ) under accession number DSM 23780. Also provided are a composition comprising Lactobacillus plantarum CMU995 and a method for inhibiting pathogens, protecting the gastrointestinal tract, and/or protecting the urinary tract in a mammal comprising administrating an effective amount of Lactobacillus plantarum CMU995 to the mammal.

Claims

1. An isolated Lactobacillus plantarum CMU995, deposited at the Food Industry Research and Development Institute (FIRDI) in Taiwan under accession number BCRC 910472 and in the German Collection of Microorganisms and Cell Cultures (DSMZ) under accession number DSM 23780.

2. The Lactobacillus plantarum CMU995 as claimed in claim 1, which is able to adhere onto a gastrointestinal tract and/or a urinary tract in a mammal.

3. The Lactobacillus plantarum CMU995 as claimed in claim 1, wherein the mammal is a human being.

4. The Lactobacillus plantarum CMU995 as claimed in claim 1, which is able to inhibit the growth of a pathogen in a mammal.

5. The Lactobacillus plantarum CMU995 as claimed in claim 4, wherein the pathogen is selected from a group consisting of Helicobacter pylori, Campylobacter jejuni, Salmonella spp., Escherichia spp. Staphylococcus spp., Shigella flexneri, Clostridium perfringens, Candida albicans, and combinations thereof.

6. The Lactobacillus plantarum CMU995 as claimed in claim 5, wherein the pathogen is Helicobacter pylori.

7. The Lactobacillus plantarum CMU995 as claimed in claim 4, wherein the mammal is a human being.

8. The Lactobacillus plantarum CMU995 as claimed in claim 1, which is able to inhibit a pathogen from adhering onto a gastrointestinal tract and/or a urinary tract in a mammal.

9. The Lactobacillus plantarum CMU995 as claimed in claim 8, wherein the pathogen is selected from a group consisting of Helicobacter pylori, Campylobacter jejuni, Salmonella spp., Escherichia spp. Staphylococcus spp., Shigella flexneri, Clostridium perfringens, Candida albicans, and combinations thereof.

10. The Lactobacillus plantarum CMU995 as claimed in claim 9, wherein the pathogen is Helicobacter pylori.

11. The Lactobacillus plantarum CMU995 as claimed in claim 8, wherein the mammal is a human being.

12. A composition comprising the Lactobacillus plantarum CMU 995 as claimed in claim 1.

13. The composition as claimed in claim 12, which is used for inhibiting a pathogen, protecting a gastrointestinal tract, and/or protecting a urinary tract in a mammal.

14. The composition as claimed in claim 13, wherein the pathogen is selected from a group consisting of Helicobacter pylori, Campylobacter jejuni, Salmonella spp., Escherichia spp., Staphylococcus spp., Shigella flexneri, Clostridium perfringens, Candida albicans, and combinations thereof.

15. The composition as claimed in claim 13, wherein the pathogen is Helicobacter pylori.

16. The composition as claimed in claim 12, wherein the composition is a pharmaceutical composition, a feed, drink, a nutrition supplement, a diary product, food, health food, a spray, or a suppository.

17. A method for inhibiting a pathogen, protecting a gastrointestinal tract in a mammal, and/or protecting a urinary tract in a mammal, comprising administrating an effective amount of the Lactobacillus plantarum CMU995 as claimed in claim 1 to the mammal.

18. The method as claimed in claim 17, wherein the pathogen is selected from a group consisting of Helicobacter pylori, Campylobacter jejuni, Salmonella spp., Escherichia spp., Staphylococcus spp., Shigella flexneri, Clostridium perfringens, Candida albicans, and combinations thereof.

19. The method as claimed in claim 18, wherein the pathogen is Helicobacter pylori.

20. The method as claimed in claim 17, wherein the mammal is a human being.